Contact us
 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Author(s)
Juliano Sartori and Rodolfo Herberto Schneider
Full-Text PDF
XML 380 Views
DOI:10.17265/2328-2150/2017.03.003
Affiliation(s)
ABSTRACT
Breast cancer is a complex and heterogeneous disease with different clinical
outcomes. The investigations of new biomolecular
markers are essential to know the prognosis and improve the clinical management
of patients. The SIRT-1 (sirtuin-1) is a
histone deacetylase implicated in various epigenetic critical functions for the
cells and the maintenance of genomic stability. The objective of this study is to investigate the grade of expression of the SIRT-1 (sirtuin-1) and the
prognostic value in overall survival of women with breast cancer. Retrospective
cohort of 457 women with breast cancer has been researched, undergoing treatment in Erechim-RS from 2003 to
2013 and followed until July 2015. The degree of SIRT-1 expression was
investigated by immunohistochemistry in 123 patients (26.9%) of the cohort.
The OS (overall survival)
from specific disease and risk of death from breast cancer were estimated by
Kaplan-Meier and Cox’s proportional risks. The median age of 57.4 years cohort
with OS of 79.6% in 5 years and 69.1% at 10 years, with follow-up time of 61.9
months are revealed in this
work. The SIRT-1
overexpression was found in 6.5% of cases and characterized a subgroup of women
with shorter survival and increased risk of death from breast cancer (HR = 2.66; 95% CI 1.03 to 6.86; p = 0.043) and adjusted
by age (HR = 2.86; 95% CI 1.11 to
7.38; p = 0.030), histology (HR = 2.79; 95% CI 1.07 to 7.28; p = 0.036), lymph nodes
(HR = 2.73; 95% CI 1.06 to 7.04; p = 0.037), Her-2 (HR = 2.82; 95% CI 1.07 to 7.44; p = 0.036);
chemotherapy (HR = 2.90; 95% CI 1.11
to 7.60; p = 0.030) and
radiotherapy (HR = 2.71; 95% CI 1.05
to 7.01; p = 0.040). In
regressive multivariate models adjusted for age, status of axillary lymph
nodes, Her-2 expression and proliferation index (Ki-67), the grade of
expression of the SIRT-1 maintained association with poor prognosis. From the study, it
can be concluded that the assessment of the
SIRT-1 expression is an independent prognostic biomarker in breast cancer.
KEYWORDS
Breast cancer, sirtuin-1, survival, carcinogenesis, repression epigenetics, prognosis, immunohistochemistry.
Cite this paper
Sartori, J., and Schneider, R. H. 2017. “Expression Grade Sirtuin-1 (SIRT-1) in Tumor Tissue in Women with Breast Cancer: A New Biomarker Prognosis?” Journal of Pharmacy and Pharmacology 5 (3): 125-138.
References